News
CBD recognized as a mainstream product by the World Health Organization
Feb
The WHO(World Health Organization), a specialized agency of the UN(United Nations), has recommended the declassification of cannabis in the schedule of the Single Convention on Narcotic Drugs in a report released on January 26, 2019.
What are the implications of this recommendation on medical cannabis?
Since 2016, the WHO (World Health Organization) and a committee of experts, are considering the declassification of cannabis in the schedule of the Single Convention on Narcotic Drugs. According to a report published last January 26, the WHO recommends that cannabis, currently in Schedule IV passes into Schedule III, thus recognizing these therapeutic values by integrating Cannabinoid preparations to this schedule.
This recommendation of declassification of cannabis is in no way an encouragement to the consumption of this product, but will allow to relax the international laws so that certain molecules that make up cannabisThe use of cannabis as a therapeutic drug.
This declassification will result in the authorization to prepare any type of mixture, solid or liquid, based on cannabinoids and mainly cannabidiol, not exceeding 0.2% THC.
But the recommendation of the WHO will have to be validated by the Commission on Narcotic Drugs of the United Nations which will meet in March 2019, so that this declassification of cannabis is officially established in the Single Convention on Narcotic Drugs.
Although the member countries of the United Nations are not obliged to apply this Convention to the letter, the therapeutic virtues of certain cannabinoids such as CBD are recognized by an international medical organization.
Sources:
► https://www.norml.fr/l-oms-recommande-de-reclasser-le-cannabis/
► https://www.norml.fr/lorganisation-mondiale-de-la-saute-autorise-le-cannabis-light/
All of our articles are written by Vincent, a member of our team who is educated on the subject of cannabinoids and has a degree in Chemistry. The facts retranscribed through our information blog are taken from international scientific literature, whose sources are verifiable and quoted at the end of each of our articles.
All these data are the property of SWISS MEDICAL CANNABIS SA. It is protected by the 91/250/EEC and 96/9/EC directives, which grant copyright protection to computer programs and databases respectively. SWISS MEDICAL CANNABIS SA. reserves the right to take legal action against any copy or reproduction of our information. We also reserve the right to bring an action for damages, in accordance with Article L. 331-1-3 of the CPI, which states that "to determine the damages, the court shall take into consideration the negative economic consequences, including loss of earnings, suffered by the injured party, the profits made by the author of the infringement of rights and the moral prejudice caused to the owner of these rights as a result of the infringement.
Pingback: Medical cannabis approved by the European Parliament | Swiss Medical Cannabis SA
Pingback: National Cancer Institute approves cannabinoid use | Swiss Medical Cannabis SA